INT9467

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1992
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 14
Total Number 16
Disease Relevance 10.49
Pain Relevance 0.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (APOB) small molecule metabolic process (APOB) endoplasmic reticulum (APOB)
enzyme binding (APOB) lipid metabolic process (APOB) extracellular space (APOB)
Anatomy Link Frequency
plasma 2
bile 1
APOB (Homo sapiens)
Pain Link Frequency Relevance Heat
Bile 13 99.24 Very High Very High Very High
Inflammation 20 94.64 High High
ischemia 5 93.52 High High
dexamethasone 2 93.40 High High
Angina 15 87.48 High High
cytokine 5 87.24 High High
Bioavailability 37 70.88 Quite High
cINOD 7 61.08 Quite High
adenocard 3 53.12 Quite High
beta blocker 1 33.92 Quite Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 358 100.00 Very High Very High Very High
Hyperlipidemia 43 99.90 Very High Very High Very High
Repression 1 98.10 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

83 95.80 Very High Very High Very High
Coronary Artery Disease 178 95.04 Very High Very High Very High
INFLAMMATION 25 94.64 High High
Disease 51 91.76 High High
Hypertension 22 90.36 High High
Diabetes Mellitus 98 89.72 High High
Atherosclerosis 77 89.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
They reported that treatment with statins led to significant reduction in total cholesterol, LDL, and apolipoprotein B.
Negative_regulation (reduction) of apolipoprotein B associated with disorder of lipid metabolism
1) Confidence 0.57 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004511 Disease Relevance 1.01 Pain Relevance 0
Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100.
Negative_regulation (defective) of apolipoprotein B-100 in plasma associated with disorder of lipid metabolism
2) Confidence 0.43 Published 1992 Journal Atherosclerosis Section Title Doc Link 1418096 Disease Relevance 0.52 Pain Relevance 0.09
Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100.
Negative_regulation (reduction) of apolipoprotein B-100 in plasma associated with disorder of lipid metabolism
3) Confidence 0.43 Published 1992 Journal Atherosclerosis Section Title Doc Link 1418096 Disease Relevance 0.52 Pain Relevance 0.09
Mean baseline total cholesterol was 187.9 mg/dL (LDL-C 112.7 mg/dL), however 3 months after commencing statins mean LDL-C was reduced by 37% to 70.8 mg/dL (P < 0.01) with a corresponding 24% (P < 0.01) reduction in apoB.
Negative_regulation (reduction) of apoB associated with disorder of lipid metabolism
4) Confidence 0.43 Published 2008 Journal Atherosclerosis Section Body Doc Link PMC2292239 Disease Relevance 0.26 Pain Relevance 0
Patients with class V mutations, in whom the internalized LDL particles cannot be released into the endosomes1, show a higher decrease in LDL and apolipoprotein B levels after treatment with statins.30 This finding was contrary to the results of Sun et al who reported that patients with severe mutations had higher LDL cholesterol during treatment with simvastatin,31 while Sijbrands et al reported similar lipid-lowering response in heterozygous patients with either mRNA-positive or mRNA-negative LDL receptor mutations.32
Negative_regulation (decrease) of apolipoprotein B associated with disorder of lipid metabolism
5) Confidence 0.42 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004511 Disease Relevance 0.45 Pain Relevance 0
In an early phase III pivotal trial, LERN (40 mg of laropiprant/2000 mg of niacin) significantly improved lipid parameters compared to placebo, and resulted in 18.4% reduction in LDL-C, 20% increase in HDL-C, 25.8% reduction in TG, 19.8% decrease in non-HDL-C cholesterol, 18.8% decrease in ApoB and 6.9% increase in ApoA-1.41 In this study, two-thirds of patients were on a statin at enrollment and were randomized to LERN, ERN or placebo.
Negative_regulation (decrease) of ApoB associated with disorder of lipid metabolism
6) Confidence 0.27 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857616 Disease Relevance 0.33 Pain Relevance 0
As monotherapy, it may be used to reduce TG levels in patients with severe hypertriglyceridemia, to reduce total cholesterol, LDL-C, apo B, and TG, and to increase HDL-C in patients with primary hyperlipidemia or mixed hyperlipidemia.
Negative_regulation (reduce) of apo B associated with hyperlipidemia and disorder of lipid metabolism
7) Confidence 0.20 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922314 Disease Relevance 1.58 Pain Relevance 0
Trilipix with simvastatin 20 mg resulted in greater reductions in apo B protein levels compared with simvastatin 20 mg (P < 0.012).98
Negative_regulation (reductions) of apo B
8) Confidence 0.20 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922314 Disease Relevance 0.46 Pain Relevance 0
In addition, fibrates have been shown to decrease cholesterol synthesis by inhibiting hydroxymethylglutamyl-coenzyme A reductase and to increase cholesterol excretion in the bile pool.55,60,61 Fenofibrate is able to reduce apo B levels, primarily as a result of reduced synthesis and secretion of TG, and not by directly influencing apo B production.45

Effects on nonlipid parameters

Negative_regulation (reduce) of apo B in bile associated with bile
9) Confidence 0.20 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922314 Disease Relevance 0.82 Pain Relevance 0.08
We and other researchers have reported previously that PLTP deficiency in mice results in markedly decreased in apoB-containing lipoproteins in the circulation[35] and PLTP overexpression stimulation of VLDL secretion[36].
Negative_regulation (decreased) of apoB
10) Confidence 0.17 Published 2009 Journal Nutr Metab (Lond) Section Body Doc Link PMC2793253 Disease Relevance 0.68 Pain Relevance 0.03
Compared with pravastatin, atorvastatin-treated patients experienced significantly greater decreases in LDL-C (55% vs 32% at 12 months), total cholesterol, triglycerides, and apolipoprotein B at months 3 and 12 (all p < 0.001).
Negative_regulation (decreases) of apolipoprotein B associated with disorder of lipid metabolism
11) Confidence 0.06 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2546474 Disease Relevance 0.74 Pain Relevance 0.09
High-density lipoprotein (HDL) cholesterol was determined after precipitation of Apo-lipoprotein B by an enzymatic method (Boehringer).
Spec (determined) Negative_regulation (precipitation) of Apo-lipoprotein B associated with disorder of lipid metabolism
12) Confidence 0.05 Published 2009 Journal PPAR Research Section Body Doc Link PMC2792957 Disease Relevance 0.51 Pain Relevance 0.10
Tricor is indicated as adjunctive therapy to diet in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb) to increase high-density lipoprotein cholesterol (HDL-C), reduce triglycerides (TG), reduce low-density lipoprotein cholesterol (LDL-C), reduce total cholesterol (Total-C), and reduce apolipoprotein B (Apo B).
Negative_regulation (reduce) of apolipoprotein B associated with hyperlipidemia and disorder of lipid metabolism
13) Confidence 0.02 Published 2008 Journal International Journal of Nanomedicine Section Body Doc Link PMC2626933 Disease Relevance 0.39 Pain Relevance 0.04
The GC-independent repression of AP-1 and NF-kappa B activities was further demonstrated by overexpressing a ligand-binding deficient GR mutant.
Negative_regulation (deficient) of mutant associated with repression
14) Confidence 0.01 Published 1999 Journal Gene Ther. Section Abstract Doc Link 10435109 Disease Relevance 0.68 Pain Relevance 0.31
The involvement of endosomal trafficking of internalized DENV particles was further evaluated by using molecular inhibitor of dominant negative mutant of Rab5 (a protein required for early endosome formation and trafficking) [40].
Negative_regulation (inhibitor) of mutant
15) Confidence 0.01 Published 2010 Journal Virol J Section Body Doc Link PMC2825209 Disease Relevance 0.46 Pain Relevance 0
In addition, these compounds reduce the levels of mutant p53.
Negative_regulation (reduce) of mutant p53
16) Confidence 0.00 Published 1996 Journal Oncogene Section Abstract Doc Link 8632912 Disease Relevance 0.80 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox